Business
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central RoleMELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced plans to investigate the phenomenon of “mesenchymal drift”—an emerging area of research that may help unlock the mechanisms behind the reversal of chronic
About this update from Propanc Biopharma, Inc.
[{"type":"image","alt":"Propanc Biopharma, Inc.","displaySize":"","headline":null,"caption":"Propanc Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zPt00rMvD.xBRkZ0lNSFVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/1d46ee439e4fd6f462d5d9ac2d16195b","width":300,"height":68}},"lazy":false},{"type":"text","content":"Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central Role","length":86,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced plans to investigate the phenomenon of “mesenchymal drift”—an emerging area of research that may help unlock the mechanisms behind the reversal of chronic diseases. The concept, advanced by leaders in the field including Altos Labs, Inc., aligns with Propanc’s expanding research efforts into how its lead product candidate, PRP, may influence the epithelial-to-mesenchymal transition (EMT) and related pathways central not only to cancer progression but also other chronic diseases. Fibrosis, a major cause of age-related organ failure, represents one such application. Propanc recently filed a patent application describing a PRP-based treatment method for fibrotic disease.","length":935,"tagName":"p"},{"type":"text","content":"The epithelial-to-mesenchymal transition (EMT) is a fundamental biological process in which epithelial cells lose their structural characteristics and acquire migratory, mesenchymal properties. However, excessive or uncontrolled mesenchymal activity can contribute to tumor growth or organ dysfunction, including fibrosis.","length":332,"tagName":"p"},{"type":"text","content":"“Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest,” said Dr. Julian Kenyon, Propanc’s Chief Scientific Officer. Professor Macarena Perán, Joint Lead Researcher from the University of Jaén in Granada, Spain, con...